Cancer Medicine is an open access, interdisciplinary oncology journal providing rapid publication of research from global biomedical researchers across the cancer sciences. Indexed in Medline and Web of Science, we cover the breadth of oncology: clinical cancer research, cancer biology, cancer prevention, and bioinformatics.

Journal Metrics

  • 5CiteScore
  • 3.1Journal Impact Factor
  • 15%Acceptance rate
  • 9 days Submission to first decision
view all metrics

Reasons to submit your manuscript to Cancer Medicine:

  • High standard, rigorous peer review
  • International Editorial Board
  • Indexed in Medline and Web of Science
  • Rapid publication
  • Open access and fully compliant with open access mandates
  • Authors retain copyright
  • Wiley's tradition in publishing excellence

Cancer Medicine is a peer-reviewed Wiley Open Access journal publishing quality research with speed and efficiency. For further information, visit the Wiley Open Access website.

On the Cover

Skip slideshow
Cover Image
The cover image is based on the article Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models by Syeda Afshan et al., https://doi.org/10.1002/cam4.70240.
Cover Image
The cover image is based on the article Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics by Wei Guo et al., https://doi.org/10.1002/cam4.70039.
Cover Image
The cover image is based on the Research Article Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma by Zhan Yang et al., https://doi.org/10.1002/cam4.7308.
Cover Image
The cover image is based on the Research Article Clinical Analysis of EV-Fingerprint to Predict Grade Group 3 and Above Prostate Cancer and Avoid Prostate Biopsy by Adrian Fairey et al., https://doi.org/10.1002/cam4.6216.
more >

Articles

RESEARCH ARTICLE
Open access

Outcome and Challenges in the Treatment of Pediatric Hodgkin Lymphoma With Euronet-PHL-C1 Protocol: Experience From a Resource-Limited Country

Elie Bechara, Toufic Eid, Arwa El-Dhuwaib, Hani Tamim, Dolly Noun, Raphah Borghol, Zaher Chakhachiro, Miguel R. Abboud, Samar Muwakkit, 
  •  31 July 2025
RESEARCH ARTICLE
Open access

Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real‐World Evidence Approach

Leonardo Rojas, Natalia Sánchez, Jorge Ceballos, Antonio Robles, Carlos A. Badillo, Virginia Abello, Carlos Bonilla, William A. Mantilla, Jairo Zuluaga, Gilberto Lopes, Oscar Arrieta, Andrés F. Cardona, 
  •  31 July 2025

Graphical Abstract

Economic Benefits of Sponsored Clinical Trials in Cancer for the Colombian Healthcare System: A Real-World Evidence Approach Issue 15, 2025

Sponsored clinical trials in Colombia could generate significant cost savings for the healthcare system by covering treatment expenses for cancer patients. An analysis at an oncology center estimated that with 20% patient participation, annual savings would reach USD 48.8 million, and up to USD 1.22 billion over 5 years with 100% inclusion. This would contribute to the system's financial sustainability and improve access to innovative therapies.

BRIEF COMMUNICATION
Open access

Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase

Daniele Caracciolo, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone, 
  •  31 July 2025
BRIEF COMMUNICATION
Open access

Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer

Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S. Bhakta, Patrick M. Boland, Michael J. Cavnar, Michelle L. Churchman, Hassan Hatoum, Lyen C. Huang, Joseph Kim, Richard Kim, Robert W. Lentz, Sarbajit Mukherjee, Mary T. O'Donnell, Benjamin Quartey, Matthew J. Reilley, Robert J. Rounbehler, Bodour Salhia, Bryan P. Schneider, Carlos H. Chan, 
  •  31 July 2025
RESEARCH ARTICLE
Open access

The COMFORT Trial: A Randomised Control Trial Comparing Group-Based COMpassion-FOcused Therapy Techniques and Breathing Pattern ReTraining With Treatment as Usual on the Psychological Functioning of Patients Diagnosed With Cancer Recurrence

Sinead Lynch, Rachel Pender, Carolyn Ingram, Clodagh Finnerty, Damien Lowry, Yvonne O'Meara, Donal J. Brennan, 
  •  30 July 2025
More articles

Articles with the most citations published in the Last 2 Years according to CrossRef. The citation counts listed reflect the total number of all citations to date.

Open access

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi, 

Graphical Abstract

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma Issue 20, 2023

Daratumumab and isatuximab are two CD38 targeting antibodies approved for the treatment of multiple myeloma. In this review we summarize the biology of the CD38 target, various assets targeting CD38, mechanism of action of daratumumab and isatuximab and their immunomodulatory properties, resistance mechanisms and approaches to overcome resistance against CD38 antibodies. We also discuss the similarities and differences of the mechanism of action of these two antibodies, which might be important for immune modulation and overcoming immunosuppression in the myeloma bone marrow environment.

Open access

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial

Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani, 
Open access

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Ali Esparham, Mahboubeh Tajaldini, Mehdi Karimi-Shahri, 
More articles

Recent issues

Latest news

More news >